Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
University of Alabama at Birmingham, Birmingham, Alabama Accel Research Site - Achieve - Birmingham - ERN - PPDS, Vestavia Hills, Alabama Stanford Center for Excellence in Pulmonary Biology, Palo Alto, California University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd, Kansas City, Kansas University of North Carolina Clinical Research Center, Chapel Hill, North Carolina UPMC Montefiore Hospital, Pittsburgh, Pennsylvania TTS Research, Boerne, Texas